Trial Profile
Prognostic Value of EGFR Expression, KRAS Mutation and Tumor Sideness in Patients With Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI as a Third- or Fourth-line Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 12 Oct 2018 New trial record